Xtandi 40 MG tablet 120S
Ended Awarded
- Contract number
- SPE2DB26FYM46
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for 120 tablets of XTANDI 40 mg on October 31, 2025, with an ultimate completion date of November 3, 2025. This firm fixed-price delivery order represents no set-aside designation and leverages DMS Pharmaceutical Group's established capacity as a critical pharmaceutical supplier within the federal military medical supply chain. XTANDI is an oncology medication used in prostate cancer treatment, aligning with the vendor's extensive portfolio of specialty pharmaceuticals and branded medications distributed to Department of Defense healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036. As a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, DMS Pharmaceutical Group serves as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. The parent IDC authorizes the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support recurring medical supply needs of military healthcare facilities worldwide, demonstrating the company's pivotal role in sustaining Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FYM46?
SPE2DB26FYM46 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 31, 2025.
How much is contract SPE2DB26FYM46 worth?
The government has obligated $4,170 on SPE2DB26FYM46.
Is contract SPE2DB26FYM46 an order under another contract?
Yes. SPE2DB26FYM46 is a delivery order under SPE2DB22D9316, an indefinite delivery contract.
Was contract SPE2DB26FYM46 competed?
The extent of competition for SPE2DB26FYM46 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award